Zahn Alexandra, Hinz Ulf, Karner Max, Ehehalt Robert, Stremmel Wolfgang
Department of Gastroenterology, University Hospital Heidelberg, Germany.
Inflamm Bowel Dis. 2006 Nov;12(11):1058-67. doi: 10.1097/01.mib.0000234134.35713.d2.
Inflammatory bowel disease (IBD) impairs health-related quality of life (HRQOL). Our aim was to investigate whether the improvement in the Clinical Activity Index (CAI) and Endoscopic Activity Index (EAI) is significantly correlated with the advancement of HRQOL and its dimensions in ulcerative colitis (UC) and to assess whether demographic and disease-related factors influence patients' experience of HRQOL. This examination was performed in the context of our recently published study of the anti-inflammatory effect of phosphatidylcholine in UC.
Sixty patients with chronic active UC were treated with phosphatidylcholine or placebo over 3 months. They were asked to complete the Inflammatory Bowel Disease Questionnaire-Deutschland (IBDQ-D) before and after the study. The correlations between CAI and EAI and IBDQ-D scores were calculated. Demographic and disease-related factors were obtained.
A statistically significant lowering of CAI and EAI after treatment in the phosphatidylcholine group led to a statistically significant improvement in HRQOL (r = -0.623, P = 0.0003 for CAI; r = -0.511, P = 0.005 for EAI). Constant disease activity indexes in the placebo group accompanied constant HRQOL (r = -0.747, P < 0.0001 for CAI; r = -0.634, P = 0.0002 for EAI). Furthermore, besides a few exceptions, significant correlations between CAI and EAI and the 4 dimensions of the IBDQ-D could be shown. Demographic parameters did not significantly influence the IBDQ-D scores.
This study points out the strong relationship between CAI and EAI and all domains of HRQOL in patients with UC. Therefore, the IBDQ-D is a valid and reliable assessment tool that reflects changes in the health status of UC patients. It is a useful measure of therapeutic efficacy and should be used in clinical trials in IBD.
炎症性肠病(IBD)会损害健康相关生活质量(HRQOL)。我们的目的是研究临床活动指数(CAI)和内镜活动指数(EAI)的改善是否与溃疡性结肠炎(UC)患者HRQOL及其维度的改善显著相关,并评估人口统计学和疾病相关因素是否会影响患者的HRQOL体验。这项检查是在我们最近发表的关于磷脂酰胆碱对UC抗炎作用的研究背景下进行的。
60例慢性活动性UC患者接受了为期3个月的磷脂酰胆碱或安慰剂治疗。他们被要求在研究前后完成《德国炎症性肠病问卷》(IBDQ-D)。计算CAI、EAI与IBDQ-D评分之间的相关性。获取人口统计学和疾病相关因素。
磷脂酰胆碱组治疗后CAI和EAI有统计学意义的降低,导致HRQOL有统计学意义的改善(CAI:r = -0.623,P = 0.0003;EAI:r = -0.511,P = 0.005)。安慰剂组持续的疾病活动指数伴随着持续的HRQOL(CAI:r = -0.747,P < 0.0001;EAI:r = -0.634,P = 0.0002)。此外,除了少数例外,CAI、EAI与IBDQ-D的4个维度之间存在显著相关性。人口统计学参数对IBDQ-D评分没有显著影响。
本研究指出了UC患者CAI、EAI与HRQOL所有领域之间的密切关系。因此,IBDQ-D是一种有效且可靠的评估工具,可反映UC患者健康状况的变化。它是衡量治疗效果的有用指标,应用于IBD的临床试验。